NYSE · HAE
Healthcare · Medical - Instruments & Supplies
$118.21
Down-$0.52 (-0.44%)
Updated Oct 21, 2026, 7:07 AM
SID Score
6.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance · HAE
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 20, 2026
HAE closed at $118.21 after 21 trading sessions, up 8.93% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | $119.50 | $120.50 | $117.205 | $118.21 | 585K |
| Oct 19, 2026 | $118.07 | $119.8199 | $117.00 | $118.73 | 392.22K |
| Oct 16, 2026 | $121.83 | $121.84 | $118.1914 | $118.28 | 471.52K |
| Oct 15, 2026 | $122.20 | $122.46 | $118.65 | $121.29 | 747.65K |
| Oct 14, 2026 | $121.81 | $122.53 | $119.55 | $121.11 | 592.14K |
| Oct 13, 2026 | $122.80 | $123.77 | $121.045 | $121.72 | 829.19K |
| Oct 12, 2026 | $118.70 | $122.24 | $118.355 | $122.06 | 895.09K |
| Oct 9, 2026 | $119.81 | $121.1925 | $116.515 | $118.69 | 1.25M |
| Oct 8, 2026 | $115.00 | $121.00 | $111.66 | $119.47 | 2.78M |
| Oct 7, 2026 | $103.48 | $104.02 | $101.315 | $101.71 | 625.58K |
| Oct 6, 2026 | $104.92 | $105.58 | $102.80 | $103.52 | 542.05K |
| Oct 5, 2026 | $104.29 | $106.26 | $103.645 | $104.68 | 652.65K |
| Oct 2, 2026 | $104.58 | $105.70 | $103.61 | $104.68 | 328.57K |
| Oct 1, 2026 | $105.71 | $106.67 | $103.51 | $104.37 | 454.25K |
| Sep 30, 2026 | $105.42 | $105.78 | $103.54 | $105.30 | 508.9K |
| Sep 29, 2026 | $104.99 | $106.52 | $104.60 | $105.80 | 451.22K |
| Sep 28, 2026 | $105.14 | $106.215 | $104.435 | $105.79 | 472.15K |
| Sep 25, 2026 | $105.72 | $106.58 | $104.71 | $105.30 | 492.6K |
| Sep 24, 2026 | $106.67 | $108.22 | $105.92 | $106.00 | 416.8K |
| Sep 23, 2026 | $108.56 | $110.28 | $106.70 | $106.82 | 704.88K |
| Sep 22, 2026 | $109.26 | $110.14 | $108.38 | $108.52 | 446.6K |
The latest Smart Investors Daily articles mentioning HAE.
Company
Market Activity
Research & News
HAE research
Company profile and research snapshot.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 9, 2026 | Mizuho | Outperform | — |
| Oct 9, 2026 | Barrington Research | Outperform | — |
| Oct 8, 2026 | BTIG | Buy | — |
| Sep 17, 2026 | Citigroup | Buy | — |
| Sep 3, 2026 | Raymond James | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 16, 2026
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Benzinga · Oct 9, 2026
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $118 to $140.
Benzinga · Oct 9, 2026
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $95 to $140.
SeekingAlpha · Oct 9, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HAE.
